Glioblastoma pseudoprogression and true progression reveal spatially variable transcriptional differences.

ABSTRACT: Post-resection radiologic monitoring to identify areas of new or progressive enhancement concerning for cancer recurrence is critical during patients with glioblastoma follow-up. However, treatment-related pseudoprogression presents with similar imaging features but requires different clinical management. While pathologic diagnosis is the gold standard to differentiate true progression and pseudoprogression, the lack of objective clinical standards and admixed histologic presentation creates the needs to (1) validate the accuracy of current approaches and (2) characterize differences between these entities to objectively differentiate true disease. We demonstrated using an online RNAseq repository of recurrent glioblastoma samples that cancer-immune cell activity levels correlate with hete

SUBMITTER: Wang W 

PROVIDER: S-EPMC10694987 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature